Displaying drugs 5876 - 5900 of 6768 in total
Z-Val-Ala-Asp fluoromethyl ketone
Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which can be used directly with purified enzymes. It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.
Experimental
LB54640
LB54640 is orally-administered small molecule agonist of the melanocortin 4 receptor.
Investigational
Ethyl Dimethyl Ammonio Propane Sulfonate
Experimental
Cefatrizine
Experimental
Dersalazine
Investigational
Idraparinux
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Investigational
Acetrizoic acid
Acetrizoic acid presents the molecular formula of 3-acetamidol-2,4,6-triiodobenzoic acid and it is the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953 and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th,...
Withdrawn
Bocidelpar
Investigational
Recifercept
Investigational
Rodatristat
Investigational
(2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid
Experimental
(2S)-2-HYDROXY-2H-CHROMENE-2-CARBOXYLIC ACID
Experimental
(5S)-5-Iododihydro-2,4(1H,3H)-pyrimidinedione
Experimental
PHENYL[1-(N-SUCCINYLAMINO)PENTYL]PHOSPHONATE
Experimental
(2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
Experimental
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
CRA_16847
Experimental
5-phospho-D-arabinohydroxamic acid
Experimental
CP-271485
Experimental
OptPA
Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.
Investigational
p-Toluenesulfonic acid
Experimental
Tuspetinib
Tuspetinib (HM-43239) is under investigation in clinical trial NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Danicamtiv
Danicamtiv is under investigation in clinical trial NCT04572893 (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities).
Investigational
Tobevibart
Tobevibart is under investigation in clinical trial NCT05612581 (A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection).
Investigational
Displaying drugs 5876 - 5900 of 6768 in total